课题基金 / 基金详情

Cell-mediated immune responses to HIV-1 in GALT

Cell-mediated immune responses to HIV-1 in GALT
GALT 中细胞介导的针对 HIV-1 的免疫反应
批准号:
6775648
负责人:
Barbara L. Shacklett
金额:
$35.06万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-11 至 2007-10-31

项目摘要

项目成果

Barbara L. Shacklett的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请方提供):这些研究的目的是更好地了解肠道相关淋巴组织(GALT)中CD8+ T细胞应答、病毒复制和CD4+ T细胞耗竭之间的关系,并阐明GALT T细胞执行抗病毒免疫效应功能的能力。我们已经开发了方法来评估从人直肠组织新鲜分离的抗原特异性T细胞的表型和功能。对于SPECIFICAIM 1,我们将评估GALT和血液中HIV特异性CDS+ T细胞的频率、广度和功能异质性。我们推测,粘膜组织中抗原特异性CD8+ T细胞特异性的频率和范围将大于血液。血液和直肠活检样本将从(i)30名HIV感染男性和女性以及10名对照的横断面研究和(ii)20名HIV感染个体的纵向研究中获得。对于特异性目的2,我们将评估HAART对GALT中病毒载量和抗原特异性CD4+和CD8+ T细胞应答的影响。我们预测,在HAART期间,HIV特异性CD8+ T细胞应答的幅度普遍下降,同时组织病毒载量下降,尽管有些人可能在GALT中存在残留病毒和HIV特异性CD8+ T细胞。我们预测,减少病毒载量和CD4+ T细胞的再增殖将提供部分重建的CD4+ T细胞的反应,非HIV抗原,并可能导致增加细胞因子的生产HIV特异性CD8+ T细胞在GALT。在这些研究中,我们将对20名开始HAART的个体进行为期两年的纵向抽样。对于特异性AIM 3,我们将评估GALT中抗原特异性CD8+ T细胞的细胞毒性效应子功能。初步结果表明,(i)血液中的HIV特异性CTL表达低水平的穿孔素,(ii)GALT中所有CD8+ T细胞的穿孔素表达相对于血液降低,和(iii)颗粒酶A和穿孔素差异表达。我们推测GALT中的CD8+ T细胞可能功能受损。我们将比较HIV感染者和健康对照者血液和GALT中抗原特异性CD8+ T细胞的细胞毒性功能。我们还将测试替代假设来解释GALT中穿孔素表达水平明显较低的原因。
英文摘要
DESCRIPTION (provided by applicant): The purpose of these studies is to better understand the relationship between CD8+ T-cell responses, viral replication and CD4+ T-cell depletion in gut-associated lymphoid tissue (GALT), and to clarify the ability of GALT T-cells to perform antiviral immune effector functions. We have developed methods to assess the phenotype and function of antigen-specific T-cells freshly isolated from human rectal tissue. For SPECIFICAIM 1, we will assess the frequency, breadth and functional heterogeneity of HIV-specific CDS+ T-cells in GALT and blood. We hypothesize that the frequency and range of specificities of antigen-specific CD8+ T-cells will be greater in mucosal tissues than in blood. Blood and rectal biopsy samples will be obtained from(i) a cross-sectional study of 30 HIV-infected men and women and 10 controls and (ii) a longitudinal study of20 HIV-infected individuals. For SPECIFIC AIM 2, we will assess the effects of HAART on viral load and antigen-specific CD4+ and CD8+ T-cell responses in GALT. We predict a general decline in the magnitude of HIV-specific CD8+ T-cell responses concurrent with decreased tissue viral load during HAART, although some individuals may harbor residual virus and HIV-specific CD8+ T-cells in GALT. We predict that reduced viral load and CD4+ T-cell repopulation will provide partial reconstitution of CD4+ T-cell responses to non-HIV antigens, and may lead to increased cytokine production by HIV-specific CD8+ T-cells in GALT. For these studies, we will perform longitudinal sampling over a two-year period of 20 individuals initiating HAART. For SPECIFIC AIM 3, we will assess the cytotoxic effector functions of antigen-specific CD8+T-cells in GALT. Preliminary results suggest that (i) HIV-specific CTL in blood express low levels of perforin, (ii) perforin expression by all CD8+ T-cells is decreased in GALT relative to blood, and (iii) granzyme A and perforin are differentially expressed. We hypothesize that CD8+ T-cells in GALT may be functionally impaired. We will compare the cytotoxic function of antigen-specific CD8+ T-cells in blood and GALT of HIV-infected individuals and healthy controls. We will also test alternate hypotheses to explain the apparent low levels of perforin expression in GALT.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UC Davis Shared Astrios Cell Sorter
  • 批准号:
    8826347
  • 项目类别:
  • 资助金额:
    $55.47万
  • 财政年份:
    2015
  • 负责人:
    Barbara L. Shacklett
  • 依托单位:
HIV-Specific T Cell Responses in Rectal Mucosa
  • 批准号:
    8077555
  • 项目类别:
  • 资助金额:
    $23.07万
  • 财政年份:
    2010
  • 负责人:
    Barbara L. Shacklett
  • 依托单位:
CNS Immune/Inflammatory Biomarkers in HIV Controllers
  • 批准号:
    7939616
  • 项目类别:
  • 资助金额:
    $22.55万
  • 财政年份:
    2009
  • 负责人:
    Barbara L. Shacklett
  • 依托单位:
Immunopathogenesis of HIV in the Female Reproductive Tract
  • 批准号:
    7684933
  • 项目类别:
  • 资助金额:
    $37.76万
  • 财政年份:
    2009
  • 负责人:
    Barbara L. Shacklett
  • 依托单位:
海外基金